Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4,077 Mln
Revenue (TTM)
$16 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
13.3
Industry P/E
--
EV/EBITDA
1.1
Div. Yield
0 %
Debt to Equity
0.4
Book Value
$--
EPS
$-2
Face value
--
Shares outstanding
146,075,743
CFO
$-514.11 Mln
EBITDA
$-533.58 Mln
Net Profit
$-766.06 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Centessa Pharmaceuticals (CNTA)
| 58.7 | 47.8 | 58.7 | 200.0 | 117.6 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Centessa Pharmaceuticals (CNTA)
| 49.3 | 109.2 | 156.8 | -72.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Centessa Pharmaceuticals (CNTA)
|
39.7 | 4,076.9 | 16.0 | -242.7 | -1,430.4 | -70.6 | -- | 13.3 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of... idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Address: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT Read more
CEO & Director
Dr. Saurabh Saha M.D., Ph.D.
CEO & Director
Dr. Saurabh Saha M.D., Ph.D.
Headquarters
Altrincham
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Centessa Pharmaceuticals plc (CNTA) is $39.69 (NASDAQ) as of 02-Apr-2026 16:06 EDT. Centessa Pharmaceuticals plc (CNTA) has given a return of 117.64% in the last 3 years.
Since, TTM earnings of Centessa Pharmaceuticals plc (CNTA) is negative, P/E ratio is not available.
The P/B ratio of Centessa Pharmaceuticals plc (CNTA) is 13.26 times as on 31-Mar-2026, a 237 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-8.10
|
4.76
|
|
2023
|
-5.06
|
3.23
|
|
2022
|
-1.33
|
0.86
|
|
2021
|
-2.21
|
1.72
|
|
2020
|
--
|
--
|
The 52-week high and low of Centessa Pharmaceuticals plc (CNTA) are Rs 40.25 and Rs 9.60 as of 04-Apr-2026.
Centessa Pharmaceuticals plc (CNTA) has a market capitalisation of $ 4,077 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Centessa Pharmaceuticals plc (CNTA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.17
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.